Literature DB >> 17593033

The linear effects of alpha-thalassaemia, the UGT1A1 and HMOX1 polymorphisms on cholelithiasis in sickle cell disease.

Nisha Vasavda1, Stephan Menzel, Sheila Kondaveeti, Emma Maytham, Moji Awogbade, Sybil Bannister, Juliette Cunningham, Andrew Eichholz, Yvonne Daniel, Iheanyi Okpala, Tony Fulford, Swee Lay Thein.   

Abstract

Serum bilirubin levels and predisposition to gallstones in sickle cell disease (SCD) are influenced by genetic variation in the hepatic uridine diphosphate (UDP)-glucuronosyltransferase (UGT1A1) gene, but the association is not consistent. This study investigated whether variation in the gene encoding haem oxygenase (HMOX1), a rate-limiting enzyme upstream of UGT1A in the haem catabolic pathway, and alpha-thalassaemia could explain some of the inconsistent effects. The UGT1A1 [TA](n) and HMOX1 [GT](n) promoter polymorphisms and alpha globin genotypes were determined in 263 SCD patients (199 HbSS, 5 HbS/beta(0), 59 HbSC). Detection of gallstones was based on ultrasound of the liver/biliary tree. Regression analysis showed that serum bilirubin levels and the incidence of gallstones were strongly associated with the number of UGT1A1 [TA] repeats in all subjects (P < 0.0001 and P < 0.01, respectively). While HMOX1 genotype had no effect, co-inheritance of alpha-thalassaemia reduced serum bilirubin levels in all SCD patients independently of the number of UGT1A1 [TA] repeats. Each additional [TA] repeat is associated with an increase in mean serum bilirubin levels of 21% and cholelithiasis risk of 87% in SCD.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17593033     DOI: 10.1111/j.1365-2141.2007.06643.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  22 in total

1.  Concept of the pathogenesis and treatment of cholelithiasis.

Authors:  Vasiliy Ivanovich Reshetnyak
Journal:  World J Hepatol       Date:  2012-02-27

Review 2.  Genetic modifiers of sickle cell disease.

Authors:  Martin H Steinberg; Paola Sebastiani
Journal:  Am J Hematol       Date:  2012-05-28       Impact factor: 10.047

3.  Genome-wide association meta-analysis for total serum bilirubin levels.

Authors:  Andrew D Johnson; Maryam Kavousi; Albert V Smith; Ming-Huei Chen; Abbas Dehghan; Thor Aspelund; Jing-Ping Lin; Cornelia M van Duijn; Tamara B Harris; L Adrienne Cupples; Andre G Uitterlinden; Lenore Launer; Albert Hofman; Fernando Rivadeneira; Bruno Stricker; Qiong Yang; Christopher J O'Donnell; Vilmundur Gudnason; Jacqueline C Witteman
Journal:  Hum Mol Genet       Date:  2009-05-04       Impact factor: 6.150

4.  The effect of UGT1A1 promoter polymorphism in the development of hyperbilirubinemia and cholelithiasis in hemoglobinopathy patients.

Authors:  Suad AlFadhli; Hassan Al-Jafer; Mays Hadi; Mashael Al-Mutairi; Rasheeba Nizam
Journal:  PLoS One       Date:  2013-10-30       Impact factor: 3.240

Review 5.  Measuring success: utility of biomarkers in sickle cell disease clinical trials and care.

Authors:  Ram Kalpatthi; Enrico M Novelli
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

6.  Alpha thalassemia, but not βS-globin haplotypes, influence sickle cell anemia clinical outcome in a large, single-center Brazilian cohort.

Authors:  Betânia Lucena Domingues Hatzlhofer; Diego Antonio Pereira-Martins; Igor de Farias Domingos; Gabriela da Silva Arcanjo; Isabel Weinhäuser; Diego Arruda Falcão; Isabela Cristina Cordeiro Farias; Jéssica Vitória Gadelha de Freitas Batista; Luana Priscilla Laranjeira Prado; Jéssica Maria Florencio Oliveira; Thais Helena Chaves Batista; Marcondes José de Vasconcelos Costa Sobreira; Rodrigo Marcionilo de Santana; Amanda Bezerra de Sá Araújo; Manuela Albuquerque de Melo; Bruna Vasconcelos de Ancântara; Juan Luiz Coelho-Silva; Ana Beatriz Lucas de Moura Rafael; Danízia Menezes de Lima Silva; Flávia Peixoto Albuquerque; Magnun Nueldo Nunes Santos; Ana Cláudia Dos Anjos; Fernando Ferreira Costa; Aderson da Silva Araújo; Antonio Roberto Lucena-Araújo; Marcos André Cavalcanti Bezerra
Journal:  Ann Hematol       Date:  2021-02-13       Impact factor: 3.673

Review 7.  Intravascular hemolysis and the pathophysiology of sickle cell disease.

Authors:  Gregory J Kato; Martin H Steinberg; Mark T Gladwin
Journal:  J Clin Invest       Date:  2017-03-01       Impact factor: 14.808

Review 8.  Molecular basis of β thalassemia and potential therapeutic targets.

Authors:  Swee Lay Thein
Journal:  Blood Cells Mol Dis       Date:  2017-06-20       Impact factor: 3.039

9.  Influence of UGT1A1 promoter polymorphism, α-thalassemia and βs haplotype in bilirubin levels and cholelithiasis in a large sickle cell anemia cohort.

Authors:  Jéssica V G F Batista; Gabriela S Arcanjo; Thais H C Batista; Marcondes J Sobreira; Rodrigo M Santana; Igor F Domingos; Betânia L Hatzlhofer; Diego A Falcão; Diego A Pereira-Martins; Jéssica M Oliveira; Amanda S Araujo; Luana P M Laranjeira; Fernanda S Medeiros; Flávia P Albuquerque; Dulcinéia M Albuquerque; Magnun N Santos; Manuela F Hazin; Ana C Dos Anjos; Fernando F Costa; Aderson S Araujo; Antonio R Lucena-Araujo; Marcos A Bezerra
Journal:  Ann Hematol       Date:  2021-02-01       Impact factor: 3.673

10.  Do Alpha Thalassemia, Fetal Hemoglobin, and the UGT1A1 Polymorphism have an Influence on Serum Bilirubin Levels and Cholelithiasis in Patients with Sickle Cell Disease?

Authors:  Laura Alencastro de Azevedo; Joyce Bonazzoni; Sandrine Comparsi Wagner; Mariela Granero Farias; Christina M Bittar; Liane Daudt; Simone Martins de Castro
Journal:  Mol Diagn Ther       Date:  2017-08       Impact factor: 4.074

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.